EMV Capital plc

EMV Capital plc is a UK-based deep tech and life sciences venture capital investment group with an international portfolio of innovative companies. The firm focuses on identifying, investing in, and nurturing high-growth businesses in the healthcare, sustainability, and technology sectors. It employs a capital-light investment approach, utilizing its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital Partners Limited. This strategy allows EMV Capital to support a broad portfolio while maintaining flexibility and scalability. The firm is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

EMV Capital's investment strategy is centered on adding significant value through proactive portfolio management, guiding companies towards key value inflection points, and achieving investment returns through strategic liquidity events. The firm targets a diverse range of sectors, including biotechnology, life sciences, medical devices, robotics, sustainability, and therapeutics. It invests across various stages, from pre-seed to late-stage companies, and has a geographical focus that includes the United Kingdom, United States, Israel, and the European Union.

The firm's portfolio includes companies such as Glycotest, Inc., a US-based liver disease diagnostics company, and ProAxsis Limited, a UK-based medical diagnostics company. EMV Capital's approach is to develop customized investment strategies for its portfolio companies, combining its network of private investors, institutional VCs, and corporate VC funds. This model enables the firm to effectively support its portfolio companies and drive value creation through strategic exits and liquidity events.